Press Release: 20/20 BioLabs Reports Third Quarter 2026 Financial Results and Recent Business Updates

Dow Jones11-17

OneTest$(TM)$ Revenue Increased 4.1% to $1.36 Million for First Nine Months of 2026, with Gross Margin Expanding to 32.8%

Vermont Executes Two-Year Firefighter Cancer Screening Contract with Testing Expected to Contribute Revenue in Q4

New Laboratory Franchise Model and 2027 Licensing Plans Aim to Broaden OneTest(TM) Distribution

Cash of $3.63 Million and No Outstanding Debt as of September 30, 2026

GAITHERSBURG, Md., Nov. 16, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) ("20/20 BioLabs" or the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today reported its financial and operational results for the third quarter ended September 30, 2026.

Third Quarter and Recent Operational Highlights

   -- OneTest(TM) revenue increased 4.1% to $1.36 million for the first nine 
      months of 2026, representing 92.8% of total revenue. 
 
   -- OneTest(TM) gross profit increased 15.6% to $0.45 million for the first 
      nine months of 2026, with gross margin expanding to 32.8% from 29.5%. 
 
   -- Third quarter revenue was $0.38 million, compared to $0.42 million in the 
      prior year period, reflecting the timing of firefighter cancer screening 
      programs. 
 
   -- Vermont executed a two-year contract specifying OneTest(TM) Premium for 
      its statewide cancer screening program covering approximately 4,500 
      firefighters. Testing is expected to begin contributing to revenue in Q4 
      2026. 
 
   -- Continued OneTest(TM) testing through Maryland's state-funded firefighter 
      cancer screening program, with 18 groups of fire departments awarded more 
      than $520,000 in grants. 
 
   -- Introduced a OneTest(TM) laboratory franchise model to expand 
      distribution through regional laboratories under a royalty-based 
      structure. 
 
   -- Announced plans to begin licensing its patented protein tumor marker 
      testing technology to laboratories in the U.S. and internationally in 
      2027. 
 
   -- Entered into $1.30 million of non-cancelable customer contracts during 
      the first nine months of 2026. 
 
   -- Cash and cash equivalents totaled $3.63 million as of September 30, 2026, 
      with no outstanding borrowings. 

Management Commentary

President and Chief Executive Officer Jonathan Cohen commented, "OneTest(TM) revenue grew 4.1% through the first nine months of the year, with gross profit increasing 15.6%. While third quarter revenue was below the prior year, much of this reflected the timing of our state-funded firefighter cancer screening programs. Maryland completed a significant portion of its testing in the second quarter, while the start of Vermont's program shifted into the fourth quarter. Vermont has now executed its two-year contract, and we expect testing to begin contributing to revenue before year-end."

"We are also working on new ways to reach more customers. Our franchise model would allow established regional laboratories to offer OneTest(TM) in their markets, without requiring us to build a national sales force. We have received preliminary interest from laboratories in the United States and plan to begin licensing our protein tumor marker approach to clinical laboratories in 2027."

"With more than 25,000 firefighters screened to date, we are continuing to build the real-world evidence to support our regulatory strategy. We believe recent developments in the MCED testing industry are encouraging, and we remain focused on our goal of obtaining FDA authorization and Medicare reimbursement for OneTest(TM) for Cancer by the end of 2028," concluded Cohen.

Chief Financial Officer Alan Bergman added, "We ended the third quarter with $3.63 million in cash and no outstanding borrowings, compared to $1.03 million in cash at year-end 2025. Our net loss narrowed to $1.38 million from $1.51 million in the second quarter, while operating expenses declined 4.0% sequentially."

"Gross margin was lower this quarter due to reduced testing volume, but our laboratory has the capacity to support additional testing without a corresponding increase in certain operating costs. As testing under the Vermont contract and other programs increases, we expect to benefit from better utilization of our existing laboratory capacity while continuing to manage expenses," concluded Bergman.

Third Quarter 2026 Financial Results

Total revenue for the three months ended September 30, 2026 was $0.38 million, compared to $0.42 million in the prior year period. OneTest(TM) revenue was $0.35 million, compared to $0.36 million, and represented 92.8% of total revenue, up from 86.3%. The decrease primarily reflected the timing of state-funded firefighter cancer screening programs.

Total cost of revenue was $0.28 million, compared to $0.27 million in the prior year period.

Gross profit was $0.10 million, compared to $0.15 million in the prior year period. Gross margin was 25.5%, compared to 34.7%, reflecting lower testing volume and the impact of fixed laboratory costs.

Operating expenses were $1.49 million, compared to $0.95 million in the prior year period and $1.55 million in Q2 2026. The year-over-year increase primarily reflected higher public company expenses.

Total other income, net, was $0.01 million, compared to other expense, net, of $0.03 million in the prior year period. The Company recorded no interest expense during the quarter.

Net loss was $1.38 million, compared to $0.83 million in the prior year period and $1.51 million in Q2 2026. Net loss included approximately $0.3 million in non-cash charges.

Cash and cash equivalents totaled $3.63 million as of September 30, 2026, compared to $1.03 million at year-end 2025, primarily reflecting $6.0 million in Series E preferred financing completed during the first half of 2026. The Company had no outstanding borrowings at quarter end.

First Nine Months 2026 Financial Results

Total revenue for the nine months ended September 30, 2026 was $1.46 million, compared to $1.51 million in the prior year period. OneTest(TM) revenue increased 4.1% to $1.36 million from $1.31 million, primarily driven by Maryland firefighter cancer screening programs.

Gross profit was $0.46 million, compared to $0.47 million in the prior year period. Gross margin was 31.7%, compared to 31.5%. OneTest(TM) gross profit increased 15.6% to $0.45 million, with gross margin expanding to 32.8% from 29.5%.

Total operating expenses were $4.54 million, compared to $2.89 million in the prior year period, primarily reflecting costs associated with the Company's transition to a Nasdaq-listed public company.

Net loss was $5.06 million, compared to $2.43 million in the prior year period. Net loss included approximately $2.0 million in non-cash charges and $0.98 million in other expense, net, primarily related to convertible notes converted or exchanged during the first half of 2026.

About 20/20 BioLabs

20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. OneTest(TM) for Cancer is a multi-cancer early detection blood test and OneTest(TM) for Longevity measures inflammatory biomarkers and is commercially available. OneTest's tests are designed to be affordable and accessible and can be conveniently utilized at home using new, upper-arm capillary collection devices as an alternative to traditional venipuncture. Tests are run in the Company's College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments $(CLIA)$ licensed laboratory in Gaithersburg, Maryland.

For more information visit https://2020biolabs.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts are forward-looking statements. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about our goals and strategies; our future business development, financial condition and results of operations; expected changes in our revenue, costs or expenditures; growth of and competition trends in our industry; our expectations regarding demand for, and market acceptance of, our products; our expectations regarding our relationships with investors, institutional funding partners and other parties we collaborate with; fluctuations in general economic and business conditions in the market in which we operate; and relevant government policies and regulations relating to our industry.

In some cases, you can identify forward-looking statements by terms such as "may," "could," "will," "should," "would," "expect," "plan," "intend, " "anticipate," "believe," "estimate," "predict," "potential," "project" or "continue" or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Item 1A "Risk Factors" included in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission, or the SEC, on March 31, 2026 and elsewhere in our filings with the SEC. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.

In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

Investor Relations

Chris Tyson

MZ Group

Direct: 949-491-8235

AIDX@mzgroup.us

 
                        20/20 BIOLABS, INC. 
                      CONDENSED BALANCE SHEETS 
                            (UNAUDITED) 
                                      September 30,    December 31, 
                                           2026            2025 
                                     ---------------   ------------ 
Assets 
Current assets: 
   Cash and cash equivalents          $    3,633,711   $  1,025,987 
   Accounts receivable, net                  173,985        199,954 
   Inventory                                 102,568        116,217 
   Prepaid expenses and other 
    current assets                           119,525        128,975 
                                         -----------    ----------- 
      Total current assets                 4,029,789      1,471,133 
License agreement, net                       259,893        271,143 
Property and equipment, net                   24,525         56,677 
Intangible asset, net                        205,168        202,264 
Right-of-use assets, net                     475,670        605,289 
Deferred financing costs                           -      1,507,794 
Other assets                                  23,057         23,057 
                                         -----------    ----------- 
      Total assets                    $    5,018,102   $  4,137,357 
                                         ===========    =========== 
 
Liabilities and Stockholders' 
Equity (Deficit) 
Current liabilities: 
   Accounts payable                   $    1,045,819   $    868,545 
   Accrued liabilities                       642,335        785,784 
   Accrued dividends -- Series E 
    convertible preferred stock              128,441              - 
   Deferred revenue -- current               478,937        414,871 
   Derivative liability -- current                 -        143,382 
   Convertible notes payable -- 
    current                                        -         74,611 
   Operating lease liability -- 
    current                                  195,848        175,948 
                                         -----------    ----------- 
      Total current liabilities            2,491,380      2,463,141 
                                         -----------    ----------- 
 
Long-term liabilities: 
   Convertible notes payable, net                  -        619,355 
   Deferred revenue -- long-term              29,372         41,816 
   Derivative liabilities -- 
    long-term                                      -        543,545 
   Operating lease liability -- 
    long term                                329,847        488,725 
                                         -----------    ----------- 
      Total long-term liabilities            359,219      1,693,441 
                                         -----------    ----------- 
 
Total liabilities                          2,850,599      4,156,582 
 
Commitments and contingencies 
(Note 9)                                           -              - 
 
Contingently redeemable 
convertible preferred stock: 
   Series E convertible preferred 
    stock, $0.01 par value; 45,000 
    authorized; 5,015 and 0 shares 
    issued and outstanding as of 
    September 30, 2026 and December 
    31, 2025, respectively; 
    liquidation preference of 
    $5,639,555                             1,556,307              - 
 
Stockholders' equity (deficit): 
   Series D preferred stock, $0.01 
    par value; 936,329 authorized; 
    0 and 101,565 shares issued and 
    outstanding as of September 30, 
    2026 and December 31, 2025, 
    respectively                                   -          1,016 
   Series C preferred stock, $0.01 
    par value; 3,340,909 
    authorized; 0 and 1,204,040 
    shares issued and outstanding 
    as of September 30, 2026 and 
    December 31, 2025, 
    respectively                                   -         12,040 
   Series B preferred stock, $0.01 
    par value; 3,569,405 
    authorized; 0 and 1,471,487 
    shares issued and outstanding 
    as of September 30, 2026 and 
    December 31, 2025, 
    respectively                                   -         14,715 
   Series A-2 preferred stock, 
    $0.01 par value; 800,000 
    authorized; 0 and 442,402 
    shares issued and outstanding 
    as of September 30, 2026 and 
    December 31, 2025, 
    respectively                                   -          4,424 
   Series A-1 preferred stock, 
    $0.01 par value; 978,000 
    authorized; 0 and 651,465 
    shares issued and outstanding 
    as of September 30, 2026 and 
    December 31, 2025, 
    respectively                                   -          6,515 
   Series A preferred stock, $0.01 
    par value; 1,303,000 
    authorized; 0 and 846,368 
    shares issued and outstanding 
    as of September 30, 2026 and 
    December 31, 2025, 
    respectively                                   -          8,464 
   Common stock, $0.01 par value; 
    500,000,000 and 50,000,000 
    authorized; 13,367,204 and 
    5,442,249 shares issued and 
    outstanding as of September 30, 
    2026 and December 31, 2025, 
    respectively                             133,672         54,422 
   Additional paid-in capital             38,781,013     33,126,398 
   Accumulated deficit                   (38,303,489)   (33,247,219) 
                                         -----------    ----------- 
      Total stockholders' equity 
       (deficit)                             611,196        (19,225) 
                                         -----------    ----------- 
      Total liabilities, 
       contingently redeemable 
       preferred stock and 
       stockholders' equity 
       (deficit)                      $    5,018,102   $  4,137,357 
                                         ===========    =========== 
 
 
                           20/20 BIOLABS, INC. 
                    CONDENSED STATEMENTS OF OPERATIONS 
                               (UNAUDITED) 
                        Three Months Ended          Nine Months Ended 
                           September 30,              September 30, 
                     ------------------------   ------------------------- 
                        2026          2025         2026          2025 
                     -----------   ----------   -----------   ----------- 
Revenues             $   380,216   $  417,979   $ 1,464,162   $ 1,506,859 
Cost of revenues         283,343      272,913       999,678     1,032,735 
                      ----------    ---------    ----------    ---------- 
Gross profit              96,873      145,066       464,484       474,124 
 
Operating 
expenses: 
   Sales, general 
    and 
    administrative     1,363,385      814,179     4,007,461     2,430,134 
   Research and 
    development          123,385      131,060       534,499       462,015 
                      ----------    ---------    ----------    ---------- 
Total operating 
 expenses              1,486,770      945,239     4,541,960     2,892,149 
 
Operating loss        (1,389,897)    (800,173)   (4,077,476)   (2,418,025) 
 
Other (expense) 
income: 
   Interest expense            -      (29,547)     (539,253)      (31,222) 
   Interest income        14,806        4,181        35,935        18,312 
   Loss on change 
    in fair value 
    of warrant 
    liability                  -            -      (148,766)            - 
   Loss on issuance 
    of convertible 
    note                       -            -      (326,595)            - 
   Other expense, 
    net                        -            -          (115)         (115) 
                      ----------    ---------    ----------    ---------- 
Total other 
 (expense) income         14,806      (25,366)     (978,794)      (13,025) 
Provision for 
income taxes                   -            -             -             - 
                      ----------    ---------    ----------    ---------- 
Net loss              (1,375,091)    (825,539)   (5,056,270)   (2,431,050) 
   Deemed dividend 
    on warrant 
    modifications              -            -    (1,124,676)            - 
   Preferred stock 
    dividends           (128,441)           -      (304,295)            - 
                      ----------    ---------    ----------    ---------- 
Net loss 
 attributable to 
 common 
 stockholders        $(1,503,532)  $ (825,539)  $(6,485,241)  $(2,431,050) 
                      ==========    =========    ==========    ========== 
 
Basic and diluted 
 net loss per 
 common share        $     (0.12)  $    (0.17)  $     (0.62)  $     (0.50) 
                      ==========    =========    ==========    ========== 
Weighted-average 
 common shares 
 outstanding, basic 
 and diluted          12,958,114    4,849,770    10,484,242     4,849,770 
                      ==========    =========    ==========    ========== 
 
 
                       20/20 BIOLABS, INC. 
                CONDENSED STATEMENTS OF CASH FLOWS 
                           (UNAUDITED) 
                                            Nine Months Ended 
                                              September 30, 
                                        ------------------------- 
                                           2026          2025 
                                        -----------   ----------- 
CASH FLOWS FROM OPERATING ACTIVITIES: 
Net loss                                $(5,056,270)  $(2,431,050) 
Adjustments to reconcile net loss to 
net cash used in operating 
activities: 
   Depreciation and amortization             34,601        48,743 
   Stock based compensation                 710,137       388,950 
   Amortization of license fees              18,750        16,875 
   Issuance of common stock for 
    services                                283,595             - 
   Loss on issuance of convertible 
    note                                    326,595             - 
   Amortization of right-of-use 
    assets, net of liabilities               (9,359)       (5,516) 
   Amortization of debt discount            515,583        17,238 
   Change in fair value of derivative 
    liability                               148,766             - 
Changes in operating assets and 
liabilities: 
   Accounts receivable                       25,969        (1,601) 
   Inventory                                 13,649        (7,598) 
   Prepaid expenses and other assets          9,450       (22,605) 
   Accounts payable                         254,847       256,081 
   Accrued liabilities                     (134,784)      250,109 
   Settlement liability                           -        80,000 
   Interest payable                               -        13,984 
   Deferred revenue                          51,622       (11,663) 
                                         ----------    ---------- 
      Net cash used in operating 
       activities                        (2,806,849)   (1,408,053) 
                                         ----------    ---------- 
 
CASH FLOWS FROM INVESTING ACTIVITIES: 
Purchases of intangible assets, 
 including patents                           (5,354)            - 
License agreement                            (7,500)            - 
                                         ----------    ---------- 
      Net cash used in investing 
       activities                           (12,854)            - 
                                         ----------    ---------- 
 
CASH FLOWS FROM FINANCING ACTIVITIES: 
Proceeds from issuance of convertible 
 notes payable                              250,000       576,561 
Proceeds from issuance of series D 
 preferred stock                                  -       192,338 
Proceeds from issuance of series E 
 convertible preferred stock              6,000,000             - 
Offering costs                             (822,573)            - 
                                         ----------    ---------- 
      Net cash provided by financing 
       activities                         5,427,427       768,899 
                                         ----------    ---------- 
 
Increase (decrease) in cash and cash 
 equivalents                              2,607,724      (639,154) 
Cash and cash equivalents, beginning 
 of period                                1,025,987     1,784,009 
                                         ----------    ---------- 
Cash and cash equivalents, end of 
 period                                 $ 3,633,711   $ 1,144,855 
                                         ==========    ========== 
 
Supplemental disclosures of cash flow 
information: 
   Cash paid for interest               $         -   $         - 
                                         ==========    ========== 
   Cash paid for income taxes           $         -   $         - 
                                         ==========    ========== 
 
Non-cash disclosures of cash flow 
information: 
   Conversion of preferred stock to 
    common stock                        $   393,154   $         - 
                                         ==========    ========== 
   Deferred offering costs -- issuance 
    of common stock and warrants as 
    offering costs                      $ 3,654,057   $   452,736 
                                         ==========    ========== 
   Accrued dividends on series E 
    convertible preferred stock         $   128,441   $         - 
                                         ==========    ========== 
   Relief of accounts payable through 
    the issuance of common stock        $    77,574   $         - 
                                         ==========    ========== 
   Deemed dividend on warrant 
    modifications                       $ 1,124,676   $         - 
                                         ==========    ========== 
   Issuance of preferred stock for 
    dividends on series E convertible 
    preferred stock                     $   175,854   $         - 
                                         ==========    ========== 
   Derivative liabilities recognized 
    as debt discounts                   $   541,199   $   152,384 
                                         ==========    ========== 
   Derivative liabilities reclassified 
    to equity                           $ 1,381,124   $         - 
                                         ==========    ========== 
   Conversion of convertible notes 
    payable and accrued interest to 
    common stock                        $   834,812   $         - 
                                         ==========    ========== 
   Conversion of convertible notes 
    payable and accrued interest to 
    series E convertible preferred 
    stock                               $   583,197   $         - 
                                         ==========    ========== 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment